World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
28082
World Ranking
13175
National Ranking
41

Overview

Dae Seog Heo is a researcher affiliated with Seoul National University Hospital in South Korea, with a primary focus in the field of Medicine. Their work spans various subfields, notably Oncology, Pulmonary and Respiratory Medicine, Public Health, Environmental and Occupational Health, Pathology and Forensic Medicine, and Molecular Biology.

The researcher has contributed to several topics centered on cancer and patient care. Key areas of their research include:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Palliative Care and End-of-Life Issues
  • Lymphoma Diagnosis and Treatment
  • Patient Dignity and Privacy
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics

Dae Seog Heo has published extensively, with frequent contributions in specific academic journals and venues. These include:

  • Cancer Research and Treatment
  • Korean Journal of Sports Science
  • Scientific Reports
  • Journal of Korean Medical Science
  • Research Square (Research Square)

Recent papers authored or coauthored by the researcher illustrate the range and focus of their scientific inquiries. Some of these include:

  • "Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment", 2021, Scientific Reports
  • "Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines", 2020, Journal for ImmunoTherapy of Cancer
  • "Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma", 2020, Theranostics
  • "Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma", 2020, Leukemia
  • "Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab", 2021, CHEST Journal

The researcher frequently collaborates with a set of coauthors, reflecting a network of scientific partnerships. Frequent coauthors include:

  • Bhumsuk Keam
  • Tae Min Kim
  • Dong-Wan Kim
  • Miso Kim
  • Shin Hye Yoo

Best Publications

  • Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

    Vincent A. Miller;Vincent A. Miller;Vera Hirsh;Jacques Cadranel;Yuh Min Chen

  • Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

    Sae-Won Han;Tae-You Kim;Pil Gyu Hwang;Soohyun Jeong

  • Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.

    Tae You Kim;Dong-Wan Kim;Jae-Yong Chung;Sang Goo Shin

  • Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients

    June Chul Lee;Kyung Mi Lee;Dong Wan Kim;Dae Seog Heo

  • Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

    June Koo Lee;Junehawk Lee;Sehui Kim;Soyeon Kim

  • Validation of the Korean version of the EORTC QLQ-C30.

    Y.H. Yun;Y.S. Park;E.S. Lee;S.-M. Bang

  • Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer

    Dong-Wan Kim;Dong-Wan Kim;S. Y. Kim;H. K. Kim;S. W. Kim

  • Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer

    Suresh S. Ramalingam;Fiona Blackhall;Maciej Krzakowski;Carlos H. Barrios

  • Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

    Sae-Won Han;Tae-You Kim;Yoon Kyung Jeon;Pil Gyu Hwang

  • Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

    Primo N Lara;Jean Yves Douillard;Kazuhiko Nakagawa;Joachim Von Pawel

  • Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.

    Bhumsuk Keam;Seock-Ah Im;Kyung-Hun Lee;Sae-Won Han

  • Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer

    Joon Oh Park;Sang-We Kim;Jin Seok Ahn;Cheolwon Suh

  • Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

    Chan Young Ock;Bhumsuk Keam;Sehui Kim;Ju Seog Lee

  • Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

    Se Hoon Lee;J. K. Lee;M. J. Ahn;D. W. Kim

  • Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer

    D. Y. Kim;Joo Hang Kim;S. H. Lee;T. Y. Kim

  • Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type

    Tae Min Kim;Tae Min Kim;Yeon Hee Park;Yeon Hee Park;Sang-Yoon Lee;Sang-Yoon Lee;Ji-Hoon Kim;Ji-Hoon Kim

  • Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.

    Tae Min Kim;Tae Min Kim;Ahnah Song;Dong-Wan Kim;Dong-Wan Kim;Soyeon Kim

  • MicroRNA-146a Downregulates NFκB Activity via Targeting TRAF6 and Functions as a Tumor Suppressor Having Strong Prognostic Implications in NK/T Cell Lymphoma

    Jin Ho Paik;Ji-Young Jang Jang;Yoon Kyung Jeon;Wook Youn Kim

  • Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer†

    Sae-Won Han;Pil Gyu Hwang;Doo Hyun Chung;Dong-Wan Kim

  • Elevated TGF-b1 Secretion and Downmodulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients

    June-Chul Lee;Yong-Oon Ahn;Dong-Wan Kim;Dae Seog Heo

Frequent Co-Authors

Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Yung-Jue Bang
Yung-Jue Bang Seoul National University
Seock-Ah Im
Seock-Ah Im Seoul National University Hospital
Yoon Kyung Jeon
Yoon Kyung Jeon Seoul National University Hospital
Doo Hyun Chung
Doo Hyun Chung Seoul National University
Young Tae Kim
Young Tae Kim Seoul National University Hospital
Woo Ho Kim
Woo Ho Kim Seoul National University
Dong-Young Noh
Dong-Young Noh Seoul National University
Keunchil Park
Keunchil Park The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always mean becoming a doctor. The United States offers a variety of online degree programs in healthcare fields that can open doors to rewarding roles in medicine. Many students look for the whats the easiest nursing program to get into? as an accessible first step into nursing, providing foundational skills and career mobility.

For those interested in the administrative side of healthcare, online programs are available, such as a healthcare administration associate degree online. This pathway offers fast-track options for entry-level management roles in clinics and hospitals.

Financial assistance is crucial for many students. You can explore medical billing and coding schools that accept fafsa if you’re interested in the technical aspects of healthcare but need help funding your studies.

If standardized exams are a concern, research whether do i need to take the teas test for lpn applies to your desired nursing program—some accredited options have no exam requirements.

Exploring these alternative online healthcare degrees and pathways can help you find the right fit for your interests, budget, and timeline.

Best Scientists Citing Dae Seog Heo

Trending Scientists